DrugPatentWatch Database Preview
Drugs in Development Information for BIIB074
» See Plans and Pricing
What is the development status for investigational drug BIIB074?
BIIB074 is an investigational drug.
There have been 12 clinical trials for BIIB074.
The most recent clinical trial was a Phase 1 trial, which was initiated on April 30th 2018.
The most common disease conditions in clinical trials are Neuralgia, Trigeminal Neuralgia, and Radiculopathy. The leading clinical trial sponsors are Biogen, Convergence Pharmaceuticals, and [disabled in preview].
There are fifteen US patents protecting this investigational drug and one hundred and ninety-six international patents.
Summary for BIIB074
| US Patents | 15 |
| International Patents | 196 |
| US Patent Applications | 25 |
| WIPO Patent Applications | 49 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2018-04-30) |
| Vendors | 29 |
Recent Clinical Trials for BIIB074
| Title | Sponsor | Phase |
|---|---|---|
| Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy | Biogen | Phase 1 |
| 802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia | Biogen | Phase 3 |
| Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia | Biogen | Phase 3 |
Clinical Trial Summary for BIIB074
Top disease conditions for BIIB074
Top clinical trial sponsors for BIIB074
US Patents for BIIB074
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| BIIB074 | Start Trial | Erythromelalgia treatment | Convergence Pharmaceuticals Limited (Maidenhead, GB) | Start Trial |
| BIIB074 | Start Trial | Process for preparing alpha-carboxamide pyrrolidine derivatives | Convergence Pharmaceuticals Limited (GB) | Start Trial |
| BIIB074 | Start Trial | Compounds | Glaxo Group Limited (Greenford, Middlesex, GB) | Start Trial |
| BIIB074 | Start Trial | Compounds | Convergence Pharmaceuticals Limited (London, GB) | Start Trial |
| BIIB074 | Start Trial | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-- 3S-yl-) | Glaxo Group Limited (Greenford, Middlesex, GB) | Start Trial |
| BIIB074 | Start Trial | Methods of treating bipolar disorders | Convergence Pharmaceuticals Limited (London, GB) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BIIB074
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| BIIB074 | Denmark | DK3200783 | 2034-10-03 | Start Trial |
| BIIB074 | European Patent Office | EP3200783 | 2034-10-03 | Start Trial |
| BIIB074 | Spain | ES2751688 | 2034-10-03 | Start Trial |
| BIIB074 | United Kingdom | GB201417497 | 2034-10-03 | Start Trial |
| BIIB074 | Croatia | HRP20191434 | 2034-10-03 | Start Trial |
| BIIB074 | Hungary | HUE047940 | 2034-10-03 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
